Donanemab Supplemental Application for Efficacy Approved by FDA

The U.S. Food and Drug Administration (FDA) approved a supplemental application for Donanemab (brand name Kisunla, also known as donanemab-azbt) on 2025-07-01. This approval pertains to an efficacy supplement, as indicated by the FDA's action on BLA 761248 S-4.

Background

Donanemab is a drug developed by ELI LILLY CO.. This supplemental application specifically addresses the drug's efficacy, indicating further review or expansion of data related to its effectiveness.

What this means

The FDA's approval of an efficacy supplemental application for Donanemab means that new data or information regarding the drug's effectiveness has been reviewed and accepted. While the specific details of this efficacy supplement are not provided in the immediate data, such approvals can signify updates to the drug's label, new data supporting its use, or potentially an expansion of its approved population or indication, all related to its proven effectiveness.

Source

This information was obtained from the U.S. Food and Drug Administration (FDA) on 2025-07-01. The details are available on the FDA's official website, accessdata.fda.gov, under BLA 761248.